Workflow
Fuerte Announces AGM Results and Appointment of Technical Advisors
TMX Newsfile· 2025-12-17 21:55
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Fuerte Metals Corporation (TSXV: FMT) (OTCQB: FUEMF) ("Fuerte" or the "Company") is pleased to announce the results of voting at its Annual General and Special Meeting held December 17, 2025 in Toronto, Canada. A total of 41,536,092 common shares were voted, representing 34.30% of the issued and outstanding common shares as at the record date of the meeting. Shareholders voted in favour of all items put forward by the Company.As a result:T ...
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Prnewswire· 2025-12-17 21:53
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappoi ...
The 6 biggest reveals from WBD's filing on why it rejected Paramount
Business Insider· 2025-12-17 21:52
Warner Bros. Discovery didn't just reject Paramount again on Wednesday. It also pulled back the curtain on what the bidding war was like behind the scenes. WBD advised shareholders to dismiss Paramount's $30-per-share offer for the company and stick with Netflix's bid of $27.75 per share (for only its studios and streaming business). In a filing, WBD's board called Paramount's latest bid inadequate, with significant risks and costs imposed on shareholders compared to Netflix's bid, which it said offered su ...
Micron forecasts surging revenue as computer memory demand for AI remains high
CNBC· 2025-12-17 21:51
Core Insights - Micron Technology reported fiscal first-quarter results that exceeded Wall Street expectations for both sales and earnings per share, leading to a 5% increase in shares during extended trading [1] - The company anticipates approximately $18.70 billion in revenue for the current quarter, significantly higher than the $14.20 billion expected by LSEG, with adjusted earnings per share projected at $8.42, surpassing the $4.78 consensus [1] Financial Performance - Micron achieved a net income of $5.24 billion, or $4.60 per share, in the first quarter, compared to $1.87 billion, or $1.67 per share, in the same period last year, marking a 57% year-over-year revenue increase [3] - Adjusted earnings per share were reported at $4.78, exceeding the estimated $3.95, while revenue reached $13.64 billion, surpassing the estimated $12.84 billion [4] Market Demand - The growth in AI data center capacity is significantly driving demand for high-performance and high-capacity memory and storage, with server unit demand reportedly growing in the "high teens" percentage range in 2025 [2]
Gold (XAU/USD) Price Forecast: Tight Four-Day Range – Highest Close Since October Looms
FX Empire· 2025-12-17 21:51
Range Top ResistanceA new higher swing high for the short-term advance at $4,353 was reached last Friday, resulting in three tight days of consolidation near that high. Wednesday’s high of $4,349 marked the third recent test of that resistance zone. A decisive breakout above triggers resolution of the four-day range and continuation of the short-term uptrend. Retained bullish momentum thereafter positions gold for a new trend high breakout above $4,381.Bull Trend ConfirmationThe bull trend in gold has been ...
Overlooked Stock: JBL Posts Strong Earnings, A.I. Infrastructure Guidance
Youtube· 2025-12-17 21:50
I'm Sam Vardis on the floor of the New York Stock Exchange. It's time now for overlooked stocks. So shares of Jabel are on the rise after a strong earnings report this morning.So I'm joined by George Seller, senior markets correspondent to help us get across this one. So we got some earnings today and that is at least helping the stock outperform what is otherwise a down market. Talk us through the report and the reaction we're seeing today.>> Yeah, actually, you know, quite good considering the uh the mark ...
Sierra Madre Announces Agreement to Acquire the Del Toro Silver Mine from First Majestic Silver and Concurrent $50 Million Offering of Subscription Receipts
TMX Newsfile· 2025-12-17 21:50
Addition of second production-ready asset to the Sierra Madre portfolioDel Toro mine restart to follow La Guitarra ExpansionsVancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Sierra Madre Gold and Silver Ltd. (TSXV: SM) (OTCQX: SMDRF) ("Sierra Madre" or the "Company") is pleased to announce that it has entered into a definitive agreement (the "Purchase Agreement") on December 17, 2025 to acquire the Del Toro Silver Mine in the Chalchihuites District in Mexico ("Del Toro") from First Majes ...
Northern Trust Announces Leadership Changes
Businesswire· 2025-12-17 21:50
CHICAGO--(BUSINESS WIRE)-- #assetmanagement--Northern Trust announced a number of leadership appointments, effective January 1, 2026. ...
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg (NASDAQ:NKTR)
Seeking Alpha· 2025-12-17 21:49
Nektar Therapeutics ( NKTR ) is continuing on with development of rezpegaldesleukin, following successful results in atopic dermatitis and this week's results in alopecia areata. I haven't written about NKTR since November 2024, when IScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/w ...
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Seeking Alpha· 2025-12-17 21:49
Nektar Therapeutics ( NKTR ) is continuing on with development of rezpegaldesleukin, following successful results in atopic dermatitis and this week's results in alopecia areata. I haven't written about NKTR since November 2024, when IScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/w ...